OOIR: Observatory of International Research

Papers

(The H4-Index of ACS Medicinal Chemistry Letters is 26. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Solution Conformations Shed Light on PROTAC Cell Permeability	106
Direct-to-Biology Accelerates PROTAC Synthesis and the Evaluation of Linker Effects on Permeability and Degradation	62
Decarboxylative Cross-Coupling: A Radical Tool in Medicinal Chemistry	60
Steering New Drug Discovery Campaigns: Permeability, Solubility, and Physicochemical Properties in the bRo5 Chemical Space	55
Risdiplam, the First Approved Small Molecule Splicing Modifier Drug as a Blueprint for Future Transformative Medicines	51
The Growing Importance of Chirality in 3D Chemical Space Exploration and Modern Drug Discovery Approaches for Hit-ID	46
Design and Evaluation of Bispidine-Based SARS-CoV-2 Main Protease Inhibitors	44
Potent SARS-CoV-2 mRNA Cap Methyltransferase Inhibitors by Bioisosteric Replacement of Methionine in SAM Cosubstrate	43
Optimization of Triarylpyridinone Inhibitors of the Main Protease of SARS-CoV-2 to Low-Nanomolar Antiviral Potency	42
Ulotaront: A TAAR1 Agonist for the Treatment of Schizophrenia	41
Beyond 20 in the 21st Century: Prospects and Challenges of Non-canonical Amino Acids in Peptide Drug Discovery	41
Design, Synthesis, and Biological Evaluation of Imidazopyridines as PD-1/PD-L1 Antagonists	39
Influence of Linker Attachment Points on the Stability and Neosubstrate Degradation of Cereblon Ligands	37
Structural Insights into Plasticity and Discovery of Remdesivir Metabolite GS-441524 Binding in SARS-CoV-2 Macrodomain	35
Trisubstituted Pyrrolinones as Small-Molecule Inhibitors Disrupting the Protein–RNA Interaction of LIN28 and Let-7	30
Design, Synthesis, and Biological Evaluation of Novel EGFR PROTACs Targeting Del19/T790M/C797S Mutation	30
Trends in Hit-to-Lead Optimization Following DNA-Encoded Library Screens	29
Complex Crystal Structures of EGFR with Third-Generation Kinase Inhibitors and Simultaneously Bound Allosteric Ligands	29
Discovery of the First Orally Available, Selective K_Na1.1 Inhibitor: In Vitro and In Vivo Activity of an Oxadiazole Series	29
Intriguing Antiviral Modified Nucleosides: A Retrospective View into the Future Treatment of COVID-19	28
SD-91 as A Potent and Selective STAT3 Degrader Capable of Achieving Complete and Long-Lasting Tumor Regression	28
Evaluation of 5-(Trifluoromethyl)-1,2,4-oxadiazole-Based Class IIa HDAC Inhibitors for Huntington’s Disease	28
Contemporary Computational Applications and Tools in Drug Discovery	28
Design, Synthesis, and Biological Evaluation of IRAK4-Targeting PROTACs	27
Rational Control of Molecular Properties Is Mandatory to Exploit the Potential of PROTACs as Oral Drugs	27

Discovery of Diaminopyrimidine Carboxamide HPK1 Inhibitors as Preclinical Immunotherapy Tool Compounds	27
A Warhead Substitution Study on the Coronavirus Main Protease Inhibitor Nirmatrelvir	26
Discovery of Orally Active Isofuranones as Potent, Selective Inhibitors of Hematopoetic Progenitor Kinase 1	26